{
  "docId": "019de077-691b-72c2-80d2-a28de652ce70",
  "docSlug": "7b833127c4e1241e21c155446b1ba76b",
  "documentTitle": "MindMed | Investor Presentation Deck | 42 slides",
  "authorId": "mindmed",
  "authorName": "MindMed",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 28,
  "pageCount": 42,
  "prevPage": 27,
  "nextPage": 29,
  "slideType": "appendix_methodology",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide emphasizes regulatory alignment and standard clinical trial methodology.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-691b-72c2-80d2-a28de652ce70/28",
  "deckHref": "/decks/019de077-691b-72c2-80d2-a28de652ce70",
  "deckJsonHref": "/decks/019de077-691b-72c2-80d2-a28de652ce70.json",
  "deckAnchorHref": "/decks/019de077-691b-72c2-80d2-a28de652ce70#slide-28",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.8,
        "x": 0.08,
        "y": 0.3
      },
      "kind": "list",
      "text": "Single administration of MM120 or placebo\nNo psychotherapeutic intervention\nTrial design closely aligned with subsequently issued FDA 2023 Draft Guidance\nPatients washed out of anxiety pharmacotherapy prior to randomization\nAssessed by central rater blinded to treatment assignment and visit number",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1c0cb1ed-0053-466a-bccd-5b30e1f915a1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.9,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "list",
      "text": "Standard GAD study design with endpoints that have supported registration for approved drugs\nRandomized, double-blind, placebo-controlled, 12-week trial\nEnrolled 198 patients with GAD\nFive-arm dose optimization design with 1:1:1:1:1 randomization\nPrimary endpoint: change in Hamilton Anxiety Scale (HAM-A) at week 4",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fbd1e818-eabc-43f0-b986-3749ed4801eb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.05,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "1. Source: Study MMED008 internal study documents and calculations.\n2. FDA 2023 Draft Guidance: Psychedelic Drugs: Considerations for Clinical Investigations.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e35af5e1-9b52-4010-b6ff-4ccdd864f0e6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Phase 2b Trial of MM120 Utilized Standard GAD Design and Endpoints and was Aligned with FDA Draft Guidance for Drug Class",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "498eb255-c387-4582-968c-c3ad492bbea4",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 36,
      "from": 16,
      "beatId": "c93e54c1-7fba-4f94-ae19-b53dc410f312",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The traction section spans multiple pages, showcasing the results of clinical trials and the potential of MM120.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 42,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "6a4562d9-e1ba-4048-9ae4-0523b32c6d36",
      "evidence": "The document follows the golden circle framework, starting with the company's vision (why) and presenting its approach (how) and solution (what).",
      "position": 1,
      "objective": "Presenting the company's vision and approach",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}